NEW YORK (GenomeWeb) – Agilent Technologies announced today that the US Food and Drug Administration has approved its Dako PD-L1 IHC 28-8 pharmDx complementary diagnostic for two additional indications: urothelial carcinoma (UC) and squamous cell carcinoma of the head and neck (SCCHN).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.